173 related articles for article (PubMed ID: 14599705)
21. Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes.
Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Reynish E; Vellas B
J Gerontol A Biol Sci Med Sci; 2007 Jun; 62(6):679-80. PubMed ID: 17595427
[No Abstract] [Full Text] [Related]
22. A 10-year perspective on donepezil.
Cheewakriengkrai L; Gauthier S
Expert Opin Pharmacother; 2013 Feb; 14(3):331-8. PubMed ID: 23316713
[TBL] [Abstract][Full Text] [Related]
23. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine.
Capellà D; Vidal X
Age Ageing; 2007 Mar; 36(2):234; author reply 235. PubMed ID: 17255086
[No Abstract] [Full Text] [Related]
25. Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
Psychogeriatrics; 2016 Jan; 16(1):54-61. PubMed ID: 25919986
[TBL] [Abstract][Full Text] [Related]
26. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
[TBL] [Abstract][Full Text] [Related]
27. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Hashimoto M; Kazui H; Matsumoto K; Nakano Y; Yasuda M; Mori E
Am J Psychiatry; 2005 Apr; 162(4):676-82. PubMed ID: 15800138
[TBL] [Abstract][Full Text] [Related]
28. Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Borroni B; Pettenati C; Bordonali T; Akkawi N; Di Luca M; Padovani A
Neurosci Lett; 2003 Jun; 343(3):213-5. PubMed ID: 12770699
[TBL] [Abstract][Full Text] [Related]
29. AD2000: donepezil in Alzheimer's disease.
Schneider LS
Lancet; 2004 Jun; 363(9427):2100-1. PubMed ID: 15220027
[No Abstract] [Full Text] [Related]
30. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease.
Waldemar G; Gauthier S; Jones R; Wilkinson D; Cummings J; Lopez O; Zhang R; Xu Y; Sun Y; Knox S; Richardson S; Mackell J
Int J Geriatr Psychiatry; 2011 Feb; 26(2):150-7. PubMed ID: 20597141
[TBL] [Abstract][Full Text] [Related]
31. The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
Reeves RR; Struve FA; Patrick G; Booker JG; Nave DW
Am J Geriatr Psychiatry; 1999; 7(4):349-52. PubMed ID: 10521169
[TBL] [Abstract][Full Text] [Related]
32. Serum adipokine levels modified by donepezil treatment in Alzheimer's disease.
Pákáski M; Fehér A; Juhász A; Drótos G; Fazekas OC; Kovács J; Janka Z; Kálmán J
J Alzheimers Dis; 2014; 38(2):371-7. PubMed ID: 23979024
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
34. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
35. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
[TBL] [Abstract][Full Text] [Related]
36. Donepezil for mild and moderate Alzheimer's disease.
Birks J S; Melzer D
Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620
[TBL] [Abstract][Full Text] [Related]
37. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
38. Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil.
Chapman SB; Weiner MF; Rackley A; Hynan LS; Zientz J
J Speech Lang Hear Res; 2004 Oct; 47(5):1149-63. PubMed ID: 15603468
[TBL] [Abstract][Full Text] [Related]
39. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
40. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
Sugimoto H; Ogura H; Arai Y; Limura Y; Yamanishi Y
Jpn J Pharmacol; 2002 May; 89(1):7-20. PubMed ID: 12083745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
